Concord Medical Services Holdings Limited ("Concord Medical" or the "Company") (NYSE: CCM), a healthcare provider specialized in cancer treatment, research, education, and prevention by establishing proton centers and specialty cancer hospitals and operating an extensive network of radiotherapy and diagnostic imaging centers in China, today announced that Shanghai Concord Cancer Center ("SCCC", or the "planned hospital"), a business subsidiary of an important operating platform of the Company, Meizhong Jiahe Medical Science & Technology Development Group Co., Ltd. ("Meizhong Jiahe"), has entered into an agreement (the "Agreement") with CGN Medical Technology Ltd. ("CGNMT"), a subsidiary of a China listed company, which is an exclusive rights partner of Ion Beam Applications ("IBA") in China for its Proteus Plus technology. Pursuant to the Agreement, SCCC will purchase the IBA's Proteus Plus system from CGNMT.

Situated in Shanghai New Hongqiao International Medical Center, SCCC is a premium specialty cancer hospital constructed by the Company and built in strict compliance with domestic tertiary hospital standards, the highest standards for medical institutions in China. The construction of the planned hospital was commenced in September 2017 with an estimated construction period of five years. As of the date of the Agreement, the planned hospital is still under construction. The planned hospital will cover a site area of 70 acres, with the gross floor area of 158,769 square meters and over 400 beds. The Company aims to build the planned hospital with a multi-disciplinary and standardized tumor diagnosis and treatment service system that integrates domestic and international technology and experience.